Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson's Disease

Ivonne Pedroso, Marité Garcia, Enrique Casabona, Lilia Morales, Maria Luisa Bringas, Leslie Pérez, Teresita Rodríguez, Ileana Sosa, Yordanka Ricardo, Arnoldo Padrón, Daniel Amaro, Ivonne Pedroso, Marité Garcia, Enrique Casabona, Lilia Morales, Maria Luisa Bringas, Leslie Pérez, Teresita Rodríguez, Ileana Sosa, Yordanka Ricardo, Arnoldo Padrón, Daniel Amaro

Abstract

Introduction: Treatment strategies in Parkinson's disease (PD) can improve a patient's quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced. We performed two clinical trials to evaluate the safety and tolerability of these two drugs in PD patients. In this paper we want to show the positive results of the additional cognitive tests employed, as part of the comprehensive assessment. Materials and method: Two studies were conducted in PD patients from the outpatient clinic of CIREN, including n = 10 and n = 26 patients between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The first study employed recombinant human (rhEPO) and the second an intranasal formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to evaluate global cognitive functioning, executive function, and memory. Results: The general results in both studies showed a positive response to the cognitive functions in PD patients, who were undergoing pharmacological treatment with respect to the evaluation (p < 0.05) before the intervention. Conclusions: Erythropoietin has a discrete positive effect on the cognitive functions of patients with Parkinson's disease, which could be interpreted as an effect of the neuroprotective properties of this molecules. To confirm the results another clinical trial phase III with neuroEPO is in progress, also designed to discard any influence of a placebo effect on cognition.

Keywords: Parkinson; cognitive; neuroprotection.

Conflict of interest statement

Conflicts of InterestThe authors declare no conflict of interest.

References

    1. Romo-Gutiérrez D., Petra-Yescas M.L.L., Boll M.C. Factores genéticos de la demencia en la enfermedad de Parkinson (EP) Gac. Med. Mex. 2015;151:110–118.
    1. Litvan I., Goldman J.G., Tröster A.I., Schmand B.A., Weintraub D., Petersen R.C., Mollenhauer B., Adler C.H., Marder K., Williams-Gray C.H., et al. Diagnostic Criteria for Mild Cognitive Impairment in Parkinson’s Disease: Movement Disorder Society Task Force Guidelines. Mov. Disord. 2012;27:349–356. doi: 10.1002/mds.24893.
    1. Santangelo G., Vitale C., Trojano L., Errico D., Amboni M., Barbarulo A.M., Grossi D., Barone P. Neuropsychological Correlates of Theory of Mind in Patients with Early Parkinson’s. Disease. Mov. Disord. 2012;27:98–105. doi: 10.1002/mds.23949.
    1. Janvin C.C., Aarsland D., Larsen J.P. Cognitive predictors of dementia in Parkinson’s disease: A community-based, 4-year longitudinal study. J. Geriatr. Psychiatry Neurol. 2005;18:149–154. doi: 10.1177/0891988705277540.
    1. Pillon B., Deweer B., Agid Y., Dubois B. Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. Arch. Neurol. 1993;50:374–379. doi: 10.1001/archneur.1993.00540040036010.
    1. Weintraub D., Comella C.L., Horn S. Parkinson’s Disease—Part 1: Pathophysiology, Symptoms, Burden, Diagnosis, and Assessment. Am. J. Manag. Care. 2008;14(Suppl. S2):S40–S48.
    1. Goldman J., Weis H., Stebbins G., Bernard B., Goetz C. Clinical differences among mild cognitive impairment subtypes in Parkinson’s disease. Mov. Disord. 2012;27:1129–1136. doi: 10.1002/mds.25062.
    1. Meyer P.M., Strecker K., Kendziorra K., Becker G., Hesse S., Woelpl D., Hensel A., Patt M., Sorger D., Wegner F., et al. Reduced α4β2*–nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch. Gen. Psychiatry. 2009;66:866–877. doi: 10.1001/archgenpsychiatry.2009.106.
    1. Williams C.H., Mason S.L., Evans J.R., Foltynie T., Brayne C., Robbins T.W., Barker R.A. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J. Neurol. Neurosurg. Psychiatry. 2013;84:258–264. doi: 10.1136/jnnp-2013-305277.
    1. Rascol O. “Disease-modification” trials in Parkinson disease: Target populations, endpoints and study design. Neurology. 2009;72(Suppl. S2):S51–S58. doi: 10.1212/WNL.0b013e318199049e.
    1. Olanow C.W., Hauser R.A., Jankovic J., Langston W., Lang A., Poewe W., Tolosa E., Stocchi F., Melamed E., Eyal E., et al. A Randomized, Double-Blind, Placebo-Controlled, Delayed Start Study to Assess Rasagiline as a Disease Modifying Therapy in Parkinson’s Disease (The ADAGIO Study): Rationale, Design, and Baseline Characteristics. Mov. Disord. 2008;23:2194–2201. doi: 10.1002/mds.22218.
    1. Zhao Y.J., Wee H.L., Au W.L., Seah S.H., Luo N., Li S.C., Tan L.C.S. Selegiline use is associated with a slower progression in early Parkinson’s disease as evaluated by Hoehn and Yahr Stage transition times. Parkinsonism Relat. Disord. 2011;17:194–197. doi: 10.1016/j.parkreldis.2010.11.010.
    1. Koury M.J., Bondurant M.C. The molecular mechanism of erythropoietin action. Eur. J. Biochem. 1992;210:649–663. doi: 10.1111/j.1432-1033.1992.tb17466.x.
    1. Grasso G., Sfacteria A., Meli F., Passalacqua M., Fodale V., Buemi M., Giambartino F., Iacopino D.G., Tomasello F. The role of erythropoietin in neuroprotection: Therapeutic perspectives. Drug News Perspect. 2007;20:315–320. doi: 10.1358/dnp.2007.20.5.1120219.
    1. Mainie P. Is there a role for erythropoietin in neonatal medicine? Early Hum. Dev. 2008;84:525–532. doi: 10.1016/j.earlhumdev.2008.06.002.
    1. Halitchi C.I., Munteanu M., Brumariu O. Factors influencing responsivenessto treatment in children with renal anemia in end stage renal disease. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2008;112:94–99.
    1. Badzek S., Curic Z., Krajina Z., Plestina S., Golubic-Cepulic B., Radman I. Treatment of cancer-related anemia. Coll. Antropol. 2008;32:615–622.
    1. McPherson R.J., Juul S.E. Recent trends in erythropoietin-mediated neuroprotection. Int. J. Dev. Neurosci. 2008;26:103–111. doi: 10.1016/j.ijdevneu.2007.08.012.
    1. Sawada H., Shimohama S. MPP+ and glutamate in the degeneration of nigral dopaminergic neurons. Parkinsonism Relat. Disord. 1999;5:209–215. doi: 10.1016/S1353-8020(99)00039-5.
    1. Erbaş O., Çınar B.P., Solmaz V., Çavuşoğlu T., Ateşo U. The neuroprotective effect of erythropoietin on experimental Parkinson model in rats. Neuropeptides. 2015;49:1–5. doi: 10.1016/j.npep.2014.10.003.
    1. Wu Y., Shang Y., Sun S., Liang H., Liu R. Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion induced apoptosis via the Akt/GSK-3b/ caspase-3 mediated signaling pathway. Apoptosis. 2007;12:1365–1375. doi: 10.1007/s10495-007-0065-9.
    1. Dhanushkodi A., Akano E.O., Roguski E.E., Xue Y., Rao S.K., Matta S.G., Rex T.S., McDonald M.P. A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism. Genes Brain Behav. 2013;12:224–233. doi: 10.1111/gbb.12001.
    1. Ehrenreich H., Fischer B., Norra C., Schellenberger F., Stender N., Stiefel M., Sirén A.L., Paulus W., Nave K.-A., Gold R. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130:2577–2588. doi: 10.1093/brain/awm203.
    1. Boesch S., Sturm B., Hering S., Goldenberg H., Poewe W. Scheiber-Mojdehkar BFriedreich’s Ataxia: Clinical Pilot Trial with Recombinant Human Erythropoietin. Ann. Neurol. 2007;62:521–524. doi: 10.1002/ana.21177.
    1. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck H.H., Breiter N., Jacob S., Knerlich F., et al. Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial. Mol. Med. 2002;8:495–505.
    1. Ehrenreich H., Hinze-Selch D., Stawicki S., Aust C., Knolle-Veentjer S., Wilms S., Heinz G., Erdag S., Jahn H., Degner D., et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol. Psychiatry. 2007;12:206–220. doi: 10.1038/sj.mp.4001907.
    1. Lagarto A., Bueno V., Guerra I., Valdés O., Couret M., López R., Vega Y. Absence of hematological side effects in acute and subacute nasal dosing of erythropoietin with a low content of sialic acid. Exp. Toxicol. Pathol. 2011;63:563–567. doi: 10.1016/j.etp.2010.04.008.
    1. García-Rodríguez J.C. The Therapeutic Potential of Neuro-EPO Administered Nasally on Acute Cerebrovascular Disease. Curr. Psychopharmacol. 2012;1:1–5.
    1. Pedroso I., Bringas M.L., Aguiar A., Morales L., Alvarez M., Valdés P.A., Alvarez L. Use of Cuban Recombinant Human Erythropoietin in Parkinson’s Disease Treatment. MEDICC Rev. 2012;14:11–17.
    1. Carvalho V.A., Machado T.H., Reis G.C., Tumas V., Caramelli P., Nitrini R., Porto C.S. Mattis Dementia Rating Scale (DRS) Normative data for the Brazilian middle-age and elderly populations. Dement. Neuropsychol. 2013;7:374–379.
    1. Folstein M.F., Folstein S.E., McHugh P.R. Mini mental State. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12:189–198. doi: 10.1016/0022-3956(75)90026-6.
    1. Dubois B., Slachevsky A., Litvan I., Pillon B. The FAB A frontal assessment battery at bedside. Neurology. 2000;55:1621–1626. doi: 10.1212/WNL.55.11.1621.
    1. Rey A. Rey: Test de Copia y Reproduccion de Memoria de Figura Geometrica Compleja. TEA ediciones; Madrid, Spain: 1997.
    1. García E., Rodríguez C., Martín R., Jiménez J.E., Díaz S.H.A. Test de Fluidez Verbal: Datos normativos y desarrollo evolutivo en el alumnado de primaria. Eur. J. Educ. Psychol. 2012;5:53–64. doi: 10.30552/ejep.v5i1.80.
    1. Martín R., Hernández S., Rodríguez C., García E., Díaz A., Jiménez J.E. Datos normativos para el Test de Stroop: Patrón de desarrollo de la inhibición y formas alternativas para su evaluación. Eur. J. Educ. Psychol. 2012;5:39–51. doi: 10.30552/ejep.v5i1.76.
    1. Reitan R.M. Validity of the Trail Making Test as an indicator of organic brain damage. Percept. Mot. Skills. 1958;8:271–276. doi: 10.2466/pms.1958.8.3.271.
    1. Litvan I., Aarsland D., Adler C.H., Goldman J.G., Kulisevsky J., Mollenhauer B., Rodriguez-Oroz M.C., Tröster A.I., Weintraub D. MDS Task Force on Mild Cognitive Impairment in Parkinson’s disease: Critical Review of PD-MCI. Mov. Disord. 2011;26:1814–1824. doi: 10.1002/mds.23823.
    1. Kolb B., Whishaw I. Fundamental Human Neuropsychology. 5th ed. Saunders; Philadelpia, PA, USA: 2002. Neuropsychological assesment; pp. 751–763.
    1. Victoria M.V., Ladera V. Neuropsicología de la Enfermedad de Parkinson. Rev. Neuropsicol. Neurocienc. 2012;12:219–241.
    1. Dubois B., Pillon B. Cognitive deficits in Parkinson’s disease. J. Neurol. 1997;244:2–8. doi: 10.1007/PL00007725.
    1. Aarsland D., Bronnick K., Williams-Gray C., Weintraub D., Marder K., Kulisevsky J., Burn D., Barone P., Pagonabarraga J., Allcock L., et al. Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology. 2010;75:1062–1069. doi: 10.1212/WNL.0b013e3181f39d0e.
    1. Garzón-Giraldo M.L.D., Montoya-Arenas D.A., Carvajal-Castrillón J. Perfil clínico y neuropsicológico: Enfermedad de Parkinson/enfermedad por cuerpos de Lewy. CES Med. 2015;29:255–270.
    1. Williams-Gray C.H., Evans J.R., Goris A., Foltynie T., Ban M., Robbins T.W., Brayne C., Kolachana B.S., Weinberger D.R., Sawcer S.J., et al. The distinct cognitive syndromes of Parkinson’s disease: 5 Year follow-up of the CamPaIGN cohort. Brain. 2009;132:2958–2969. doi: 10.1093/brain/awp245.
    1. Beyer M.K., Janvin C.C., Larsen J.P., Aarsland D. A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J. Neurol. Neurosurg. Psychiatry. 2007;78:254–259. doi: 10.1136/jnnp.2006.093849.
    1. Sawamoto N., Piccini P., Hotton G., Pavese N., Thielemans K., Brooks D.J. Cognitive deficits and striato-frontal dopamine release in Parkinson’s disease. Brain. 2008;131:1294–1302. doi: 10.1093/brain/awn054.
    1. Rebollo M., Montiel S. Atención y funciones ejecutivas. Rev. Neurol. 2006;42:53–57.
    1. Fernández M., Lens M., López A., Puy A., Dias J., Sobrido M. Alteraciones de la esfera emocional y el control de los impulsos en la enfermedad de Parkinson. Rev. Neurol. 2010;50:41–49.
    1. Pereira J.B., Junqué C., Martí M.J., Ramirez-Ruiz B., Bargalló N., Tolosa E. Neuroanatomical substrate of visuospatial and visuoperceptual impairment in Parkinson’s disease. Mov. Disord. 2009;24:1193–1199. doi: 10.1002/mds.22560.
    1. Uc E., Rizzo M., Anderson S., Qian S., Rodnitzky R., Dawson J. Visual dysfunction in Parkinson disease without dementia. Neurology. 2005;65:1907–1913. doi: 10.1212/01.wnl.0000191565.11065.11.
    1. Tempone Pérez S.G. El placebo en la práctica y en la investigación Clínica. An. Med. Interna (Madrid) 2007;24:249–252. doi: 10.4321/S0212-71992007000500010.
    1. Ibarra H.S. El efecto placebo en los ensayos clínicos con antidepresivos. Acta Bioethica. 2009;15:172–178.
    1. Diederich N.J., Goetz C.G. The placebo treatments in neurosciences New insights from clinical and neuroimaging studies. Neurology. 2008;71:677–684. doi: 10.1212/01.wnl.0000324635.49971.3d.
    1. Požgain I., Požgain Z., Degmečić D. Placebo and nocebo effect: A mini-review. Psychiatr. Danub. 2014;26:100–107.
    1. García-Rodríguez J.C., Teste I.S. The Nasal Route as a Potential Pathway for delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans. Sci. World J. 2009;9:970–981. doi: 10.1100/tsw.2009.103.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe